|   In the News

Undeterred by Vertex’s plans, biotech Dyne enters Duchenne drug fray


The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease.

Read more.